These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6616598)

  • 1. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
    D'Alessandro R; Gamberini G; Lozito A; Sacquegna T
    Cephalalgia; 1983 Aug; 3 Suppl 1():156-8. PubMed ID: 6616598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
    Martucci N; Manna V; Mattesi P; Troiani G; Manzoni GC; Lanfranchi M; Bono G; Micieli G
    Cephalalgia; 1983 Aug; 3 Suppl 1():151-5. PubMed ID: 6352046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new therapeutic approach to menstrual migraine].
    Rozenbaum H
    Rev Fr Gynecol Obstet; 1984; 79(7-9):581-3. PubMed ID: 6528179
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of migraine attacks through the use of dihydroergotamine.
    Neuman M; Demarez JP; Harmey JL; Le Bastard B; Cauquil J
    Int J Clin Pharmacol Res; 1986; 6(1):11-3. PubMed ID: 3514491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline.
    Bonuso S; Di Stasio E; Barone P; Steardo L
    Cephalalgia; 1983 Aug; 3 Suppl 1():175-8. PubMed ID: 6352047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial.
    Frediani F; Grazzi L; Zanotti A; Mailland F; Zappacosta BM; Bussone G
    Cephalalgia; 1991 Jul; 11(3):117-21. PubMed ID: 1909603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in migraine: treatment with dihydroergotamine-retard.
    Mastrosimone F; Iaccarino C
    Cephalalgia; 1983 Aug; 3 Suppl 1():168-70. PubMed ID: 6616599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menstrual migraine.
    Silberstein SD
    J Womens Health Gend Based Med; 1999 Sep; 8(7):919-31. PubMed ID: 10534294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
    Centonze V; Attolini E; Santoiemma L; Brucoli C; Macinagrossa G; Campanozzi F; Albano O
    Cephalalgia; 1983 Aug; 3 Suppl 1():179-84. PubMed ID: 6616601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study.
    Bousser MG; Chick J; Fuseau E; Soisson T; Thevenet R
    Cephalalgia; 1988 Sep; 8(3):187-92. PubMed ID: 3197098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Migraine prevention with dihydroergotamine].
    Heuser B; Middendorf E
    Fortschr Med; 1985 Nov; 103(41):966-70. PubMed ID: 3905548
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acupuncture as prophylaxis for menstrual-related migraine: study protocol for a multicenter randomized controlled trial.
    Zhang XZ; Zhang L; Guo J; Zeng L; Yang Y; Zhang T; Shi GX; Liu HL; Wang LP
    Trials; 2013 Nov; 14():374. PubMed ID: 24195839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of migraine with retard dihydroergotamine. Results of a multicenter study in 643 patients].
    Wörz R
    Fortschr Med; 1986 Nov; 104(43):838-42. PubMed ID: 3542767
    [No Abstract]   [Full Text] [Related]  

  • 15. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
    Pradalier A; Lantéri-Minet M; Géraud G; Allain H; Lucas C; Delgado A
    CNS Drugs; 2004; 18(15):1149-63. PubMed ID: 15581385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations.
    Allais G; Bussone G; De Lorenzo C; Castagnoli Gabellari I; Zonca M; Mana O; Borgogno P; Acuto G; Benedetto C
    Neurol Sci; 2007 May; 28 Suppl 2():S225-8. PubMed ID: 17508177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
    Marcus DA; Bernstein CD; Sullivan EA; Rudy TE
    Headache; 2010 Apr; 50(4):551-62. PubMed ID: 20236337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
    Fontanari D; Perulli L; Conte F; Tambato E; Toso V; Zanetti R
    Cephalalgia; 1983 Aug; 3 Suppl 1():189-91. PubMed ID: 6352048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.